Clinical Trials on Influensa hos fugler

Total 3857 results

University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
Mexican Emerging Infectious Diseases Clinical Research...
National Institute of Allergy and Infectious Diseases (NIAID); Instituto Nacional... and other collaborators

Completed

Characterization of Influenza-like Illness in Mexico

Influenza-like Illness

Mexico
Green Cross Corporation

Completed

Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.

Prevention of Influenza
US Department of Veterans Affairs
St. Louis University

Withdrawn

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (CCTA #0005)

Aged | Influenza Vaccines

United States
Novartis Vaccines

Completed

Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine

Influenza A (H1N1)

Italy
University of Michigan
Centers for Disease Control and Prevention

Completed

Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions

Seasonal Influenza Vaccination

United States
Abbott Rapid Dx

Recruiting

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Dx

Completed

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Diagnostics Jena GmbH

Completed

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

COVID-19 | Influenza A | Influenza Type B

United States
Jazz Pharmaceuticals

Completed

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Acute-graft-versus-host Disease | Graft-versus-host Disease

United States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
Grupo Espanol de trasplantes hematopoyeticos y...

Completed

Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. (CSM/EICH2010)

Chronic Graft-Versus-Host Disease

Spain
Ology Bioservices

Completed

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

United States
Solvay Pharmaceuticals

Completed

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

Hot Flushes, Menopause, Postmenopause

United States, Canada, Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (FBP00004)

Healthy Volunteers | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model (CR6261)

H1N1 Influenza Healthy Volunteers

United States
Huazhong University of Science and Technology
The University of Queensland

Completed

Effect of Selenium Supplementation on Influenza Vaccination

Influenza Vaccination | Selenium Supplementation

China
National Institute of Allergy and Infectious Diseases...

Completed

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Influenza A Virus Infection

United States
University of Colorado, Denver
University of California, Los Angeles

Completed

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado

Reminder Systems | Influenza Vaccines

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
Janssen Research & Development, LLC
Janssen Pharmaceuticals

Completed

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Influenza A

United States, Germany, Bulgaria, Canada, Estonia, Latvia, Belgium, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

Novel 2009 Influenza H1N1

Costa Rica
VaxInnate Corporation

Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Influenza

United States
Vanderbilt University
Centers for Disease Control and Prevention

Completed

Cell Mediated Immunity in Older Adults (CMI)

Immunity to Influenza Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H5N1 Vaccine in the Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Influenza

United States
UMN Pharma Inc.

Completed

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

Influenza

Japan
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
Hillel Yaffe Medical Center
Gan shmuel Group

Unknown

The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients

Influenza A | Swine Flu

Israel
National Institute of Allergy and Infectious Diseases...

Completed

Prospective Study of AI H5N1 in China

Influenza

China
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Guangdong Raynovent Biotech Co., Ltd

Completed

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Influenza A

China
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Guangdong Raynovent Biotech Co., Ltd

Completed

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Influenza A

China
National Institute of Allergy and Infectious Diseases...

Completed

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates

Reminder Systems | Influenza Vaccines
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Boost in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
Dr. Nechama Sharon

Unknown

Sub Populations of Immune Cells in Influenza A and B Patients

Influenza A and B

Israel
University of Zurich
Schweizerischer Nationalfonds

Completed

Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting (TransFLUas)

Human Influenza

Switzerland
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Adults

Influenza

United States
Beijing Chaoyang District Centre for Disease Control...

Completed

Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

Quadrivalent Influenza Virus Vaccine

China

3

Subscribe